The widespread use of powerful new weight-loss drugs in the United States could boost gross domestic product by 1% in the coming years as lower obesity-related complications are likely to boost workplace efficiency, according to Goldman Sachs. Some analysts have predicted the market for weight-loss drugs could reach $100 billion a year by the end of the decade, with Ozempic maker Novo Nordisk and Mounjaro producer Eli Lilly leading the race. The use of GLP-1s could increase by anywhere between 10 to 70 million consumers by 2028, Goldman Sachs said on Thursday.
Think you're too old to start buying stocks? Think again. Here's some tips.
In this piece, we will take a look at the 13 best momentum stocks to buy now. If you want to skip our overview of the different kinds of trading strategies and some latest stock market news, then you can take a look at the 5 Best Momentum Stocks To Buy Now. When it comes […]